Alzheimer’s disease can be treated in blood circulation instead of in the brain
UTHealth - 14-Jul-2022A target for Alzheimer’s disease therapy may lie in plasmapheresis or blood dialysis
Join the club for FREE to access the whole archive and other member benefits.
Associate Professor, Blood Brain Barrier and Neurological disorders at McGovern Medical School at UTHealth Houston
Dr. Urayama received his research doctorate in Pharmacology from the University of Shizouka in Japan. He completed Post-Doctoral Fellowships in Internal Medicine and Neurology respectively at the Saint Louis University School of Medicine and the University of Texas Medical School at Houston. He was trained by one of the world’s leaders in blood-brain barrier (BBB) function, Dr. William Banks. He then completed a fellowship and joined the faculty under the mentorship of Dr. Claudio Soto. He learned a great deal through them, and acquired expertise in many different areas, including the BBB and neurodegenerative diseases such as lysosomal storage, Alzheimer’s, and prion diseases.
Dr. Urayama has been an effective educator and research mentor for Medical and Graduate School students. He is enthusiastic about teaching introductory and advanced courses with current hypothesis, logic, and proof theory behind biomedical topics. He publishes his research work in first class journals, and serves as a reviewer for professional journals, and research foundations.
Visit website: https://med.uth.edu/neurology/specialty-programs/brains-research-laboratory/dr-akihiko-urayamas-lab-members/
Details last updated 31-Jul-2022
A target for Alzheimer’s disease therapy may lie in plasmapheresis or blood dialysis